These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 23823095)

  • 21. What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML?
    Deininger MW; Manley P
    Leuk Res; 2012 Mar; 36(3):253-61. PubMed ID: 21996558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
    Hu Y; Liu Y; Pelletier S; Buchdunger E; Warmuth M; Fabbro D; Hallek M; Van Etten RA; Li S
    Nat Genet; 2004 May; 36(5):453-61. PubMed ID: 15098032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic myelogenous leukemia progenitors display a genetically unstable personality.
    Rodrigues MS; Sattler M
    J Natl Cancer Inst; 2007 May; 99(9):662-3. PubMed ID: 17470729
    [No Abstract]   [Full Text] [Related]  

  • 24. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.
    Potenza L; Volzone F; Riva G; Soverini S; Martinelli S; Iacobucci I; Gnani A; Barozzi P; Forghieri F; Morselli M; Zanetti E; Maccaferri M; Baccarani M; Martinelli G; Torelli G; Luppi M
    Br J Haematol; 2009 Jul; 146(2):227-30. PubMed ID: 19545285
    [No Abstract]   [Full Text] [Related]  

  • 26. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
    Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
    Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].
    Buchdunger E
    Med Klin (Munich); 2002 Jan; 97 Suppl 1():2-6. PubMed ID: 11831067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Leucemogenesis of chronic myelogenous leukemia].
    Mahon FX
    Rev Prat; 2005 Oct; 55(15):1642-6. PubMed ID: 16334200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New insights into the pathogenesis of chronic myeloid leukaemia: towards a path to cure.
    Thielen N; Ossenkoppele GJ; Schuurhuis GJ; Janssen JJ
    Neth J Med; 2011 Oct; 69(10):430-40. PubMed ID: 22058262
    [No Abstract]   [Full Text] [Related]  

  • 30. F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.
    Oyekunle AA; Castagnetti F; Gugliotta G; Soverini S; Baccarani M; Rosti G
    Leuk Res; 2011 Jul; 35(7):e118-20. PubMed ID: 21489624
    [No Abstract]   [Full Text] [Related]  

  • 31. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
    Wongboonma W; Thongnoppakhun W; Auewarakul CU
    Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.
    Ly C; Arechiga AF; Melo JV; Walsh CM; Ong ST
    Cancer Res; 2003 Sep; 63(18):5716-22. PubMed ID: 14522890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Chronic myeloid leukemia: "archetype" of the impact of targeted therapies].
    Nasr R; Bazarbachi A
    Pathol Biol (Paris); 2012 Aug; 60(4):239-45. PubMed ID: 22743097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Flying under the radar: the new wave of BCR-ABL inhibitors.
    Quintás-Cardama A; Kantarjian H; Cortes J
    Nat Rev Drug Discov; 2007 Oct; 6(10):834-48. PubMed ID: 17853901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Can chronic myeloid leukemia be cured by tyrosine kinase inhibitor?].
    Li MQ; Liu ZG
    Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):725-8. PubMed ID: 23978030
    [No Abstract]   [Full Text] [Related]  

  • 37. Toward a cure for chronic myeloid leukemia.
    O'Hare T; Deininger MW
    Clin Cancer Res; 2008 Dec; 14(24):7971-4. PubMed ID: 19088011
    [No Abstract]   [Full Text] [Related]  

  • 38. Should we also evaluate SET together with CIP2A for the treatment with second-generation tyrosine kinase inhibitors in chronic myeloid leukemia?
    Cristóbal I; Manso R; González-Alonso P; Rojo F; García-Foncillas J
    Leukemia; 2015 Oct; 29(10):2117. PubMed ID: 26283451
    [No Abstract]   [Full Text] [Related]  

  • 39. [Management of chronic myeloid leukemia for Japanese patients in the era of TKIs].
    Usui N
    Rinsho Ketsueki; 2014 May; 55(5):497-507. PubMed ID: 24881914
    [No Abstract]   [Full Text] [Related]  

  • 40. The DESTINY of chronic myeloid leukeamia.
    Abruzzese E
    Lancet Haematol; 2017 Jul; 4(7):e303-e304. PubMed ID: 28566210
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.